NCCN VERSION 2 2015

152 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-77
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
144. Scow JS, Degnim AC, Hoskin TL, et al. Assessment of the
performance of the Stanford Online Calculator for the prediction of
nonsentinel lymph node metastasis in sentinel lymph node-positive
breast cancer patients. Cancer 2009;115:4064-4070. Available at:
.
145. van la Parra RFD, Ernst MF, Bevilacqua JLB, et al. Validation of a
nomogram to predict the risk of nonsentinel lymph node metastases in
breast cancer patients with a positive sentinel node biopsy: validation of
the MSKCC breast nomogram. Ann Surg Oncol 2009;16:1128-1135.
Available at: .
146. Werkoff G, Lambaudie E, Fondrinier E, et al. Prospective
multicenter comparison of models to predict four or more involved
axillary lymph nodes in patients with breast cancer with one to three
metastatic sentinel lymph nodes. J Clin Oncol 2009;27:5707-5712.
Available at: .
147. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence
after sentinel lymph node dissection with or without axillary dissection in
patients with sentinel lymph node metastases: the American College of
Surgeons Oncology Group Z0011 randomized trial. Ann Surg
2010;252:426-432; discussion 432-423. Available at:
.
148. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no
axillary dissection in women with invasive breast cancer and sentinel
node metastasis: a randomized clinical trial. JAMA 2011;305:569-575.
Available at: .
149. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level
I and II lymph nodes is important in breast cancer classification. The
Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer
1992;28A:1415-1418. Available at:
150. Kiricuta CI, Tausch J. A mathematical model of axillary lymph node
involvement based on 1446 complete axillary dissections in patients
with breast carcinoma. Cancer 1992;69:2496-2501. Available at:
151. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a
randomized clinical trial comparing radical mastectomy and total
mastectomy with or without radiation. N Engl J Med 1985;312:674-681.
Available at:
152. Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology
of axillary lymph nodes in breast cancer patients: a study of 115 cases
with cytologic-histologic correlation. Cancer 2008;114:89-93. Available
at:
153. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node
biopsy after neoadjuvant chemotherapy for advanced breast cancer:
results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a
French prospective multicentric study. J Clin Oncol 2009;27:726-732.
Available at: .
154. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery
after neoadjuvant chemotherapy is accurate and reduces the need for
axillary dissection in breast cancer patients. Ann Surg 2009. Available
at:
155. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy
in patients with breast cancer before and after neoadjuvant
chemotherapy (SENTINA): a prospective, multicentre cohort study.
Lancet Oncol 2013;14:609-618. Available at:
.
156. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node
surgery after neoadjuvant chemotherapy in patients with node-positive
breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA
2013;310:1455-1461. Available at:
.
157. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative
chemotherapy on the outcome of women with operable breast cancer. J